Please assess the completion status of the following clinical trial:

Trial Title: A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis:~   1. Epithelial Endometrial Cancer: histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of recurrent previously treated EEC.~  2. Epithelial Ovarian Cancer: histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of recurrent platinum-resistant/refractory EOC, primary peritoneal, or fallopian tube cancer (i.e., disease recurrence within 6 months of completion of or progression during platinum-based chemotherapy).~  3. Carcinosarcoma/Malignant Mixed Mullerian Tumors: histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of recurrent uterine or ovarian carcinosarcoma (MMMT). Patients must have had only 1 prior chemotherapeutic regimen for management of carcinosarcoma that may have been included chemotherapy (including in adjuvant setting), chemotherapy and radiotherapy, and/or consolidation/maintenance therapy.~2. Refractory or intolerant to at least one prior standard therapy(ies) for metastatic or locally advanced disease (see Inclusion Criterion #1c for Groups 5-6).~   1. If prior therapy consisted of palliative chemoradiation therapy, it will be considered one line of therapy.~  2. Prior treatment with paclitaxel as part of definitive therapy regimen is acceptable, provided the patient is not intolerant of paclitaxel.~  3. Patients who are not eligible to receive paclitaxel will be allowed to receive single agent DKN-01.~3. Tumor tissue for mandatory pre-treatment and on-treatment biopsies.~4. One or more tumors measurable on radiographic imaging as defined by RECIST 1.1.~5. Ambulatory and ≥18 years of age.~6. ECOG performance status (PS) of 0 or 1~   a. ECOG PS of 2 may be eligible upon the review and approval of the Medical Monitor.~7. Estimated life expectancy of at least 3 months, in the judgment of the Investigator.~8. Disease-free of active second/secondary or prior malignancies for ≥2 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast.~9. Acceptable liver, renal, hematologic and coagulation function~10. Females of child bearing potential and male partners of female patients must agree to use adequate contraception during the study and for 6 months after their last dose of study drug.~11. Reliable and willing to make themselves available for the duration of the study and are willing to follow study-specific procedures.~12. Provided written informed consent prior to any study-specific procedures.~Exclusion Criteria:~1. Patients with the following pure histologies of endometrial or ovarian cancer are not eligible for enrollment: germ cell, sex cord stroma, or sarcoma.~2. New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, or unstable arrhythmia.~3. Fridericia-corrected QT interval (QTcF) \> 470 msec (female) or history of congenital long QT syndrome.~4. Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy.~5. Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb), unless hepatitis C virus ribonucleic acid (HCV RNA) undetected/negative.~6. History of major organ transplant (i.e., heart, lungs, liver, or kidney).~7. History of autologous/allogenic bone marrow transplant.~8. Serious nonmalignant disease~9. Pregnant or nursing.~10. History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are symptomatic and clinically significant.~11. Symptomatic central nervous system (CNS) malignancy or metastasis.~12. Known osteoblastic bony metastasis~13. Treatment with surgery or chemotherapy within 21 days prior to study entry (42 days for nitrosoureas or mitomycin C)~14. Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to study entry.~15. Clinically significant peripheral neuropathy at the time of study entry. Patients with pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01~16. History of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil). Patients who exhibit these hypersensitivities will be eligible to receive single agent DKN-01~17. Prior radiation therapy within 14 days prior to study entry~18. Currently receiving any other investigational agent or received an investigational agent within last 30 days of study entry.~19. Previously treated with an anti-DKK1 therapy~20. Significant allergy to a pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient~21. Active substance abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DKN-01 monotherapy in recurrent EEC (Type: EXPERIMENTAL): 300mg DKN-01 monotherapy in recurrent EEC
- DKN-01+paclitaxel in recurrent EEC (Type: EXPERIMENTAL): 300mg DKN-01+paclitaxel in recurrent EEC
- DKN-01 monotherapy in recurrent EOC (Type: EXPERIMENTAL): 300mg DKN-01 monotherapy in recurrent EOC
- DKN-01+paclitaxel in recurrent EOC (Type: EXPERIMENTAL): 300mg DKN-01+paclitaxel in recurrent EOC
- DKN-01 monotherapy in carcinosarcoma (Type: EXPERIMENTAL): 600mg DKN-01 monotherapy in carcinosarcoma
- DKN-01 +paclitaxel in carcinosarcoma (Type: EXPERIMENTAL): 600mg DKN-01 +paclitaxel in carcinosarcoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete